JNJ-7706621
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively[1][2][3].
Product Specifications
CAS Number
[443797-96-4]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Aurora Kinase; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/JNJ-7706621.html
Concentration
10mM
Purity
99.39
Solubility
DMSO : ≥ 125 mg/mL
Smiles
O=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O
Molecular Formula
C15H12F2N6O3S
Molecular Weight
394.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Huang S, et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16 (14) :3639-41. Epub 2006 May 6.|[2]Matsuhashi A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012 Jul;12 (6) :625-39.|[3]Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392 (1-2) :20-8.|[4]Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65 (19) :9038-46.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B; CDK1; CDK2; CDK3; CDK4; CDK6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NB120-10454MFV500 0.1 mL
Rat Monoclonal Caspase-11 Antibody (17D9) [mFluor Violet 500 SE]
Ask
View Details